10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2026)

10x Genomics has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $200.2 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $200.2 million, up 4.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $200.2 million (up 4.77% YoY), and the FY2025 annual result was $243.8 million, up 19.82% from the prior year.
• Total Non-Current Liabilities came in at $200.2 million for Q1 2026 at 10x Genomics, down from $243.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $243.8 million in Q4 2025 to a low of $188.0 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $203.5 million (2024), against an average of $207.3 million.
• Across the five-year window, Total Non-Current Liabilities decreased 10.02% in 2023 and advanced 19.82% in 2025, its largest moves.
• 10x Genomics' Total Non-Current Liabilities stood at $220.3 million in 2022, then slipped by 0.2% to $219.8 million in 2023, then slipped by 7.44% to $203.5 million in 2024, then gained by 19.82% to $243.8 million in 2025, then fell by 17.88% to $200.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $200.2 million (Q1 2026), $243.8 million (Q4 2025), and $235.8 million (Q3 2025), per Business Quant data.